

**PUBLISHED BY  
THE MEDICAL RESEARCH SOCIETY AND THE BIOCHEMICAL SOCIETY**

**Printed in Great Britain by Spottiswoode Ballantyne Ltd.  
Colchester and London**

## AUTHOR INDEX

- ABDELHAMID, S., VECSEI, P., HAACK, D., GLESS, K.-H., WALB, D., LICHTWALD, K. & FIEGEL, P. Dissociation in the excretion of different aldosterone metabolites and unmetabolized ('free') aldosterone in hypertension 409-414
- ALAGHBAND-ZADEH, J., see Eastwood, J.B. *et al.*
- ANDERSON, G.H., JR Evidence that the acute cardiovascular response to isoprenaline is partly mediated via renin release 13-18
- ASATOOR, A.M., BENDING, M.R. & MILNE, M.D. Peptiduria in experimental Fanconi syndrome in rats 277-279
- ATKINSON, J., BOILLAT, N., PERA-BALLY, R., PETERS-HAEFEL, L. & KIRCHERTZ, E.J. Effect of chronic clonidine treatment and its abrupt cessation on mean blood pressure of rats with a normal or an elevated blood pressure 195-201
- BALLANTYNE, D., see Ballantyne, F.C. *et al.*
- BALLANTYNE, F.C., EPEMETOS, A.A., CASLAKE, M., FORSYTHE, S. & BALLANTYNE, D. The composition of low-density lipoprotein and very-low-density lipoprotein subfractions in primary hypothyroidism and the effect of hormone-replacement therapy 83-88
- BALLARD, F.J., TOMAS, F.M., POPE, L.M., HENDRY, P.G., JAMES, B.E. & MACMAHON, R.A. Muscle protein degradation in premature human infants 535-544
- BARNES, S., see Engelking, L.R. *et al.*
- BAVIERA, E., see Rafestin-Oblin, M.E. *et al.*
- BELL, C. & MCLACHLAN, E.M. Dependence of deoxycorticosterone/salt hypertension in the rat on the activity of adrenergic cardiac nerves 203-210
- BELLINI, G., FIORENTINI, R., FERNANDES, M., ONESTI, G., HESSAN, H., GOULD, A.B., BIANCHI, M., KIM, K.E. & SWARTZ, C. Neurogenic activity-angiotensin II interaction during the development and maintenance of renal hypertension in the rat 25-29
- BENDING, M.R., see Asatoor, A.M. *et al.*
- BENGIS, R.G. & COLEMAN, T.G. Antihypertensive effect of prolonged blockade of angiotensin formation in benign and malignant, one- and two-kidney Goldblatt hypertensive rats 53-62
- BENNETT, R.M. & KOKOCINSKI, T. Lactoferrin turnover in man 453-460
- BERTHELOT, P., see Pecker, F. *et al.*
- BIANCHI, M., see Bellini, G. *et al.*
- BILLING, B.H., see Gollan, J.L. *et al.*
- BOILLAT, N., see Atkinson, J. *et al.*
- BORN, W., see Dambacher, M.A. *et al.*
- BOUILLON, R., GUESENS, P., DEQUEKER, J. & DE MOOR, P. Parathyroid function in primary osteoporosis 167-171
- BRERETON, P.J., see Wootton, R. *et al.*
- BRISSET, J.M., see Rafestin-Oblin, M.E. *et al.*
- BROOM, M.F., see Goulding, A. & Broom, M.F.
- BRUCE, C., see Charles, T.J. *et al.*
- BULLEN, A.W. & LOSOWSKY, M.S. Editorial Review: Consequences of impaired splenic function 129-137
- BUSTOS, N. see Del Batlle, A.M. *et al.*
- CAMERON, I.R., see Hall, R.J.C. & Cameron, I.R.
- CAMPBELL, M.J., see Morgan, M.H. *et al.*
- CANDY, D.C.A., see Cooper, B.T. *et al.*
- CARTER, G.D., see Eastwood, J.B. *et al.*
- CASLAKE, M., see Ballantyne, F.C. *et al.*
- CHARLES, T.J., WILLIAMS, S.J., SEATON, A., BRUCE, C. & TAYLOR, W.H. Histamine, basophils and eosinophils in severe asthma 39-45
- CHUNG, Y.C., SILK, D.B.A. & KIM, Y.S. Intestinal transport of a tetrapeptide, L-leucylglycylglycylglycine, in rat small intestine *in vivo* 1-11
- CLAIRE, M., see Rafestin-Oblin, M.E. *et al.*
- CLAMP, J.R. & GOUGH, M. Study of the oligosaccharide units from mucos glycoproteins of meconium from normal infants and from cases of cystic fibrosis with meconium ileus 445-451
- CLARK, M.B., see Wootton, R. *et al.*
- CLARK, T.J.H., see Higenbottam, T. & Clark, T.J.H.
- CLARKE, E.W., JAMISON, J.P. & QUARTEY-PAPAFIO, J.B. Impairment of flow in routine gravity-fed intravenous infusions to surgical patients 515-520

- COLEMAN, T.G., see Bengis, R.G. & Coleman, T.G.; see also Norman, R.A., Jr *et al.*
- COLINA-CHOURIO, J., MCGIFF, J.C. & NASJLETTI, A. Effect of indomethacin on blood pressure in the normotensive unanaesthetized rabbit: possible relation to prostaglandin synthesis inhibition 359–365
- COLLINGS, L., see Linnell, J.C. *et al.*
- COOPER, B.T., CANDY, D.C.A., HARRIES, J.T. & PETERS, T.J. Subcellular fractionation studies of the intestinal mucosa in congenital sucrose–isomaltase deficiency 181–185
- CORVOL, P., see Nakane, H. *et al.*; see also Rafestin-Oblin, M.E. *et al.*
- CRAWFORD, G.A., SAVDIE, E. & STEWART, J.H. Heparin-released plasma lipases in chronic renal failure and after renal transplantation 155–165
- DALY, A., see Eastwood, J.B. *et al.*
- DAMBACHER, M.A., FISCHER, J.A., HUNZIKER, W.H., BORN, W., MORAN, J., ROTH, H.-R., DELVIN, E.E. & GLORIEUX, F.H. Distribution of circulating immunoreactive components of parathyroid hormone in normal subjects and in patients with primary and secondary hyperparathyroidism: the role of the kidney and of the serum calcium concentration 435–443
- DASHER, C.A., see Engelking, L.R. *et al.*
- DAWSON, J., SEYMOUR, C.A. & PETERS, T.J. Gilbert's syndrome: analytical subcellular fractionation of liver biopsy specimens. Enzyme activities, organelle pathology and evidence for subpopulations of the syndrome 491–497
- DE JONG, W., see Ten Berg, R.G.M. *et al.*
- DEL BATTLE, A.M., WIDER DE XIFRA, E.A., STELLA, A.M., BUSTOS, N. & WITH, T.K. Studies on porphyrin biosynthesis and the enzymes involved in bovine congenital erythropoietic porphyria 63–70
- DELVIN, E.E., see Dambacher, M.A. *et al.*
- DE MOOR, P., see Bouillon, R. *et al.*
- DEQUEKER, J., see Bouillon, R. *et al.*
- DERKX, F.H.M., TAN-TJONG, H.L., MAN IN 'T VELD, A.J., SCHALEKAMP, M.P.A. & SCHALEKAMP, M.A.D.H. Activation of inactive plasma renin by plasma and tissue kallikreins 351–357
- DE WARDENER, H.E., see Eastwood, J.B. *et al.*
- DLOUHA, H., KRÉČEK, J. & ZICHA, J. Effect of age on hypertensive stimuli and the development of hypertension in Brattleboro rats 273–275
- DOLLERY, C.T., see Maling, T.J.B. *et al.*
- DOWN, M.C., see Linnell, J.C. *et al.*
- DUVALDESTIN, P., see Pecker, F. *et al.*
- EASTWOOD, J.B., DALY, A., CARTER, G.D., ALAGHBAND-ZADEH, J. & DE WARDENER, H.E. Plasma 25-hydroxy-vitamin D in normal subjects and patients with terminal renal failure, on maintenance haemodialysis and after transplantation 473–476
- EDWARDS, R.H.T., see Wiles, C.M. *et al.*
- EISENREICH, M., see Meyer, D.K. *et al.*
- ELIA, M., OPPENHEIM, W.L., SMITH, R., ILIC, V. & WILLIAMSON, D.H. Changes in blood glucose and plasma insulin after intravenous galactose in human injury 249–256
- ENGELKING, L.R., BARNES, S., DASHER, C.A., NAFTEL, D.C. & HIRSCHOWITZ, B.I. Radio-labelled bile acid clearance in control subjects and patients with liver disease 499–508
- ENGLAND, J.M., see Linnell, J.C. *et al.*
- EPENETOS, A.A., see Ballantyne, F.C. *et al.*
- ESNOUF, M.P., see Falconer Smith, J.F. *et al.*
- FALCONER SMITH, J.F., VAN HEGAN, R.I., ESNOUF, M.P. & ROSS, B.D. Characteristics of renal handling of human immunoglobulin light chain by the perfused rat kidney 113–120
- FERNANDES, M., see Bellini, G. *et al.*
- FIEGEL, P., see Abdelhamid, S. *et al.*
- FIorentINI, R., see Bellini, G. *et al.*
- FISCHER, J.A., see Dambacher, M.A. *et al.*
- FORSYTHE, S., see Ballantyne, F.C. *et al.*
- FRANCIS, M.J.O., see Pointon, J.J. *et al.*
- FRY, C.H., see Poole-Wilson, P.A. *et al.*
- FUNAKAWA, S., see Kawamura, M. *et al.*
- GALINDEZ, E., see Poole-Wilson, P.A. *et al.*
- GANAPATHY, V. & RADHAKRISHNAN, A.N. Interaction of amino acids with glycyl-L-leucine hydrolysis and transport in monkey small intestine 521–527
- GARDNER, M.L.G. Superficial or membrane digestion of peptides in dinitrophenol-inhibited rat small intestine 217–220
- GARDNER, M.L.G. & PLUMB, J.A. Release of dipeptide hydrolase activities from rat small intestine perfused *in vitro* and *in vivo* 529–534
- GUESENS, P., see Bouillon, R. *et al.*
- GLESS, K.-H., see Abdelhamid, S. *et al.*
- GLORIEUX, F.H., see Dambacher, M.A. *et al.*
- GOLDEN, M.H.N. see Taruvinga, M. *et al.*

- GOLLAN, J.L., HOLE, D.R. & BILLING, B.H. The role of dietary lipid in the regulation of unconjugated hyperbilirubinaemia in Gunn rats 327-337
- GORDON, D. & PEART, W.S. Sodium excretion in man, and adaptation to a low-sodium diet: effect of intravenous sodium chloride 225-231
- GOUGH, M., see Clamp, J.R. & Gough, M.
- GOULD, A.B., see Bellini, G. *et al.*
- GOULDING, A. & BROOM, M.F. Effects of diphosphonate and colchicine administration upon acid-base changes induced in rats by bilateral nephrectomy 19-23
- GUPTA, V.J., see Wilcken, D.E.L. & Gupta, V.J.
- HAACK, D., see Abdelhamid, S. *et al.*
- HALL, R.J.C. & CAMERON, I.R. The effect of pentobarbitone on plasma and intracellular sodium, potassium and pH in rabbit cardiac and skeletal muscle 549-551
- HAMILTON, C.A., see Jones, D.H. *et al.*; see also Maling, T.J.B. *et al.*
- HANES, F.A., see Robertson, W.G. *et al.*
- HANOUNE, J., see Pecker, F. *et al.*
- HARRIES, J.T., see Cooper, B.T. *et al.*
- HARRISON, B.D.W., see Rudolf, M. *et al.*
- HATA, T., see Ogihara, T. *et al.*
- HENDRY, P.G., see Ballard, F.J. *et al.*
- HESP, R., WILLIAMS, D., RINSLER, M. & REEVE, J. A comparison of chromium sesquioxide and [<sup>51</sup>Cr]chromic chloride as inert markers in calcium balance studies 89-92
- HESP, R., see also Wootton, R. *et al.*
- HESSAN, H., see Bellini, G. *et al.*
- HEYBURN, P.J., see Robertson, W.G. *et al.*
- HIGENBOTTAM, T. & CLARK, T.J.H. A method for standardizing airway resistance for variations in lung volume 397-400
- HILTON, P.J., see Patrick, J. & Hilton, P.J.
- HIRSCHOWITZ, B.I., see Engelking, L.R. *et al.*
- HODGKINSON, A., MARSHALL, D.H. & NORDIN, B.E.C. Vitamin D and magnesium absorption in man 121-123
- HODKINSON, H.M., see Wootton, R. *et al.*
- HOLE, D.R., see Gollan, J.L. *et al.*
- HOPWOOD, J.J. & MULLER, V. Biochemical discrimination of Hurler and Scheie syndromes 265-272
- HUNZIKER, W.H., see Dambacher, M.A. *et al.*
- IKEMOTO, F., see Kawamura, M. *et al.*
- ILIC, V., see Elia, M. *et al.*
- JACKSON, A.A., see Taruvinga, M. *et al.*
- JAMES, B.E., see Ballard, F.J. *et al.*
- JAMISON, J.P., see Clarke, E.W. *et al.*
- JONES, D.A., see Wiles, C.M. *et al.*
- JONES, D.H., HAMILTON, C.A. & REID, J.L. Choice of control groups in the appraisal of sympathetic nervous activity in essential hypertension 339-344
- JONES, D.H., see also Watson, R.D.S. *et al.*
- KANE, S.P. & VINCENTI, A.C. Mucosal enzymes in human inflammatory bowel disease with reference to neutrophil granulocytes as mediators of tissue injury 295-303
- KASTNER, P.R., see Norman, R.A. *et al.*
- KATZ, A.I., see Koeppen, B.M. *et al.*
- KAWAMURA, M., IKEMOTO, F., FUNAKAWA, S. & YAMAMOTO, K. Characteristics of a renin-binding substance for the conversion of renin into a higher-molecular-weight form in the dog 345-350
- KIM, K.E., see Bellini, G. *et al.*
- KIM, Y.S., see Chung, Y.C. *et al.*
- KIRCHERTZ, E.J., see Atkinson, J. *et al.*
- KLENERMAN, L., see Wootton, R. *et al.*
- KOEPPEN, B.M., KATZ, A.I. & LINDHEIMER, M.D. Effect of general anaesthesia on renal haemodynamics in the rat 469-471
- KOKOCINSKI, T., see Bennett, R.M. & Kokocinski, T.
- KŘEČEK, J., see Dlouha, H. *et al.*
- KUMAHARA, Y., see Ogihara, T. *et al.*
- LASZLO, G., see Latimer, R.D. & Laszlo, G.
- LATIMER, R.D. & LASZLO, G. Carbon dioxide equilibration in canine lungs during rebreathing and acute alkalosis 385-388
- LAYCOCK, J.F., see Walter, S.J. *et al.*
- LEE, G. DE J., see Prichard, J.S. & Lee, G. de J.
- LEENEN, F.H.H., see Ten Berg, R.G.M. *et al.*
- LICHTWALD, K., see Abdelhamid, S. *et al.*
- LINDHEIMER, M.D., see Koeppen, B.M. *et al.*
- LINNELL, J.C., COLLINGS, L., DOWN, M.C. & ENGLAND, J.M. Distribution of endogenous cobalamin between the transcobalamins in various mammals 139-144
- LITTLER, W.A., see Watson, R.D.S. *et al.*; see also Watson, R.D.S. *et al.*
- LLEWELYN, D.E.H. Mathematical analysis of the diagnostic relevance of clinical findings 477-479
- LOSOWSKY, M.S., see Bullen, A.W. & Losowsky, M.S.

- LUNDHOLM, K. & SCHERSTÉN, T. Protein synthesis in isolated human skeletal muscle tissue: evaluation of an experimental model 221–223
- MCCONNELL, J.B., MURISON, J. & STEWART, W.K. The role of the colon in the pathogenesis of hyperchloraemic acidosis in ureterosigmoid anastomosis 305–312
- MCGIFF, J.C., see Colina-Chourio, J. *et al.*
- MCLACHLAN, E.M., see Bell, C. & McLachlan, E.M.
- MACMAHON, R.A., see Ballard, F.J. *et al.*
- MALING, T.J.B., DOLLERY, C.T. & HAMILTON, C.A. Clonidine and sympathetic activity during sleep 509–514
- MANDAI, T., see Ogihara, T. *et al.*
- MAN IN 'T VELD, A.J. see Derkx, F.H.M. *et al.*
- MARSHALL, D.H., see Hodgkinson, A. *et al.*
- MARUYAMA, A., see Ogihara, T. *et al.*
- MENARD, J., see Nakane, H. *et al.*
- MENDELSON, F.A.O. Evidence for the local occurrence of angiotensin II in rat kidney and its modulation by dietary sodium intake and converting enzyme blockade 173–179
- MEYER, D.K., EISENREICH, M. & NUTTO, D. Effect of isoprenaline on the plasma concentrations of angiotensin III in rats 401–407
- MICHAUD, A., see Rafestin-Oblin, M.E. *et al.*
- MIKAMI, H., see Ogihara, T. *et al.*
- MILNE, M.D., see Asatoor, A.M. *et al.*
- MORAN, J., see Dambacher, M.A. *et al.*
- MORGAN, M.H., READ, A.E. & CAMPBELL, M.J. Clinical and electrophysiological studies of peripheral nerve function in patients with chronic liver disease 31–37
- MULLER, V., see Hopwood, J.J. & Muller, V.
- MURISON, J., see McConnell, J.C. *et al.*
- NAFTEL, D.C., see Engelking, L.R. *et al.*
- NAKAMARU, M., see Ogihara, T. *et al.*
- NAKANE, H., NAKANE, Y., CORVOL, P. & MENARD, J. Effect of acid, trypsin and cold treatment and of renin–plasma interaction on the activity of renin secreted by rat kidney 233–240
- NAKANE, Y., see Nakane, H. *et al.*
- NASJLETTI, A., see Colina-Chourio, J. *et al.*
- NORDIN, B.E.C., see Hodgkinson, A. *et al.*
- NORMAN, R.A., JR, COLEMAN, T.G. & KASTNER, P.R. Urine reinfusion diuresis and natriuresis in rats; role of water, electrolyte and urea 187–193
- NUTTO, D., see Meyer, D.K. *et al.*
- OGIHARA, T., HATA, T., MARUYAMA, A., MIKAMI, H., NAKAMARU, M., MANDAI, T. & KUMAHARA, Y. Studies on the renin–angiotensin–aldosterone system in elderly hypertensive patients with an angiotensin II antagonist 461–463
- ONESTI, G., see Bellini, G. *et al.*
- OPPENHEIM, W.L., see Elia, M. *et al.*
- PAGE, A.J.F., see Watson, R.D.S. *et al.*
- PATRICK, J. & HILTON, P.J. Editorial Review: Characterization of sodium-transport disorders in disease: different effects upon sodium and potassium of changes in the sodium pump and in membrane permeability 289–293
- PEACOCK, M., see Robertson, W.G. *et al.*
- PEART, W.S., see Gordon, D. & Peart, W.S.
- PECKER, F., DUVALDESTIN, P., BERTHELOT, P. & HANOUNE, J. The adenylate cyclase system in human liver: characterization, subcellular distribution and hormonal sensitivity in normal or cirrhotic adult, and in foetal liver 313–325
- PERA-BALLY, R., see Atkinson, J. *et al.*
- PETERS, T.J., see Cooper, B.T. *et al.*; see also Dawson, J. *et al.*
- PETERS-HAEFELI, L., see Atkinson, J. *et al.*
- PLUMB, J.A., see Gardner, M.L.G. & Plumb, J.A.
- POINTON, J.J., FRANCIS, M.J.O. & SMITH, R. Effect of vitamin D deficiency on sarcoplasmic reticulum function and troponin C concentration of rabbit skeletal muscle 257–263
- POOLE-WILSON, P.A., GALINDEZ, E. & FRY, C.H. Effect of ouabain in therapeutic concentration on K<sup>+</sup> exchange and contraction of human and rabbit myocardium 415–420
- POPE, L.M., see Ballard, F.J. *et al.*
- PRICHARD, J.S. & LEE, G. DE J. Measurement of water distribution and transcapillary solute flux in dog lung by external radioactivity counting 145–154
- QUARTEY-PAPAFIO, J.B., see Clarke, E.W. *et al.*
- RADHAKRISHNAN, A.N., see Ganapathy, V. & Radhakrishnan, A.N.
- RAFESTIN-OBLIN, M.E., ROTH-MEYER, C., CLAIRE, M., MICHAUD, A., BAVIERA, E. BRISSET, J.M. & CORVOL, P. Are mineralocorticoid receptors present in human renal adenocarcinoma? 421–425
- READ, A.E., see Morgan, M.H. *et al.*

- REEVE, J., see Hesp, R. *et al.*; see also Wootton, R. *et al.*
- REID, J.L., see Jones, D.H. *et al.*; see also Watson, R.D.S. *et al.*
- RINSLER, M., see Hesp, R. *et al.*
- RIORDAN, J.F., see Rudolf, M. *et al.*
- ROBERTSON, W.G., HEYBURN, P.J., PEACOCK, M., HANES, F.A. & SWAMINATHAN, R. The effect of high animal protein intake on the risk of calcium stone-formation in the urinary tract 285-288
- ROSS, B.D. & TANNEN, R.L. Effect of decrease in bicarbonate concentration on metabolism of the isolated perfused rat kidney 103-111
- ROSS, B.D., see also Falconer Smith, J.F. *et al.*
- ROTH, H.-R., see Dambacher, M.A. *et al.*
- ROTH-MEYER, C., see Rafestin-Oblin, M.E. *et al.*
- RUDOLF, M., TURNER, J.A.MCM., HARRISON, B.D.W., RIORDAN, J.F. & SAUNDERS, K.B. Changes in arterial blood gases during and after a period of oxygen breathing in patients with chronic hypercapnic respiratory failure and in patients with asthma 389-396
- SAUNDERS, K.B., see Rudolf, M. *et al.*
- SAVDIE, E., see Crawford, G.A. *et al.*
- SCHALEKAMP, M.A.D.H., see Derkx, F.H.M. *et al.*
- SCHALEKAMP, M.P.A., see Derkx, F.H.M. *et al.*
- SCHERSTÉN, T., see Lundholm, K. & Scherstén, T.
- SEATON, A., see Charles, T.J. *et al.*
- SEYMOUR, C.A., see Walter, S.J. *et al.*
- SHIRLEY, D.G., see Walter, S.J. *et al.*
- SILK, D.B.A., see Chung, Y.C. *et al.*
- SLAVIN, G., see Wootton, R. *et al.*
- SMITH, R., see Elia, M. *et al.*; see also Pointon, J.J. *et al.*
- SORRELL, M.F. & TUMA, D.J. Editorial Review: Effect of alcohol on hepatic metabolism: selected aspects 481-489
- STALLARD, T.J., see Watson, R.D.S. *et al.*
- STELLA, A.M., see Del Batlle, A.M. *et al.*
- STEWART, J.H., see Crawford, G.A. *et al.*
- STEWART, W.K., see McConnell, J.B. *et al.*
- SWAMINATHAN, R., see Robertson, W.G. *et al.*
- SWARTZ, C., see Bellini, G. *et al.*
- TANNEN, R.L., see Ross, B.D. & Tannen, R.L.
- TAN-TJONG, H.L., see Derkx, F.H.M. *et al.*
- TARUVINGA, M., JACKSON, A.A. & GOLDEN, M.H.N. Comparison of <sup>15</sup>N-labelled glycine, aspartate, valine and leucine for measurement of whole-body protein turnover 281-283
- TAYLOR, E.A., see Trembath, P.W. *et al.*
- TAYLOR, W.H., see Charles, T.J. *et al.*
- TELLEZ-YUDILEVICH, M., see Wootton, R. *et al.*
- TEN BERG, R.G.M., LEENEN, F.H.H. & DE JONG, W. Plasma renin activity and sodium, potassium and water excretion during reversal of hypertension in the one-clip, two-kidney hypertensive rat 47-52
- TOMAS, F.M., see Ballard, F.J. *et al.*
- TREMBATH, P.W., TAYLOR, E.A., VARLEY, J. & TURNER, P. Effect of propranolol on the ventilatory response to hypercapnia in man 465-468
- TUMA, D.J., see Sorrell, M.F. & Tuma, D.J.
- TURNER, J.A.MCM., see Rudolf, M. *et al.*
- TURNER, P., see Trembath, P.W. *et al.*
- WALB, D., see Abdelhamid, S. *et al.*
- WALTER, S.J., LAYCOCK, J.F. & SHIRLEY, D.G. A micropuncture study of proximal tubular function after acute hydrochlorothiazide administration to Brattleboro rats with diabetes insipidus 427-434
- WALTON, R.J. Effect of intravenous sodium lactate on renal tubular reabsorption of phosphate in man 125-127
- WATSON, R.D.S., PAGE, A.J.F., LITTLER, W.A., JONES, D.H. & REID, J.L. Plasma nor-adrenaline concentrations at different vascular sites during rest and isometric and dynamic exercise 545-547
- WATSON, R.D.S., STALLARD, T.J. & LITTLER, W.A. Effects of  $\beta$ -adrenoreceptor antagonists on sino-aortic baroreflex sensitivity and blood pressure in hypertensive man 241-247
- WEN, SUNG-FENG Effect of phlorhizin on renal glucose and phosphate transport in the dog 367-374
- WIDER DE XIFRA, E.A., see Del Batlle, A.M. *et al.*
- WILCKEN, D.E.L. & GUPTA, V.J. Cysteine-homocysteine mixed disulphide: differing plasma concentrations in normal men and women 211-215
- WILES, C.M., YOUNG, A., JONES, D.A. & EDWARDS, R.H.T. Muscle relaxation rate, fibre-type composition and energy turnover in hyper- and hypo-thyroid patients 375-384
- WILLIAMS, D., see Hesp, R. *et al.*
- WILLIAMS, S.J., see Charles, T.J. *et al.*
- WILLIAMSON, D.H., see Elia, M. *et al.*
- WITH, T.K., see Del Batlle, A. M. *et al.*
- WOOTTON, R., BRERETON, P.J., CLARK, M.B., HESP, R., HODKINSON, H.M., KLENERMAN, L., REEVE, J., SLAVIN, G. & TELLEZ-

- YUDILEVICH, M. Fractured neck of femur in the elderly: an attempt to identify patients at risk 93–101
- VAN HEGAN, R.I., see Falconer Smith, J.F. *et al.*
- VARLEY, J., see Trembath, P.W. *et al.*
- VECSEI, P., see Abdelhamid, S. *et al.*
- VINCENTI, A.C., see Kane, S.P. & Vincenti, C.A.
- YAMAMOTO, K., see Kawamura, M. *et al.*
- YOUNG, A., see Wiles, C.M. *et al.*
- ZICHA, J., see Dlouha, H. *et al.*
- ZIMMERMAN, B.G. Absence of adrenergic mediation of agonist response to [Sar<sup>1</sup>, Ala<sup>8</sup>]angiotensin II in conscious normotensive and hypertensive dogs 71–81

SUBJECT INDEX

First and last page numbers of papers to which entries refer are given.  
Page numbers marked with an asterisk refer to Editorial Reviews.

- Absorption, intestinal  
  calcium 121–123  
  magnesium 121–123  
  peptides 217–220  
  vitamin D 121–123
- Absorption, renal, phosphate and sodium  
  lactate 125–127
- Acid–base balance  
  pulmonary carbon dioxide equilibration 385–388
- Acidosis  
  hyperchloraemic 305–312  
  isolated kidney 103–111  
  nephrectomy 19–23  
  ureterosigmoid anastomosis 305–312
- Adenocarcinoma, renal  
  mineralocorticoid receptors 421–425
- Adenosine triphosphate, sodium-transport disorders 289–293
- Adenylate cyclase, liver 313–325
- $\beta$ -Adrenoreceptor  
  antagonists 241–247  
  blockade 203–210  
  isoprenaline stimulation 13–18
- Age, hypertensive responses 273–275
- Airway conductance 397–400
- Airway resistance 397–400
- Albumin, serum, pulmonary water compartments 145–154
- Alcohol, hepatic metabolism 481–490\*
- Aldosterone  
  angiotensin II antagonist 461–463  
  receptors in renal adenocarcinoma 421–425  
  urinary excretion 409–414
- Aldosterone-18-glucuronide, urinary excretion 409–414
- Alkalosis, pulmonary carbon dioxide equilibration 385–388
- Alveolar–arterial difference 385–388
- Amino acids  
  intestinal transport 521–527  
  sex difference in plasma concentrations 211–215  
  skeletal muscle proteins 221–223
- $\delta$ -Aminolaevulinate dehydratase, bovine congenital erythropoietic porphyria 63–70
- $\delta$ -Aminolaevulinate synthase, bovine congenital erythropoietic porphyria 63–70
- Amino-peptidase, jejunal 1–11
- Ammonia  
  excretion in ureterosigmoid anastomosis 305–312  
  metabolism of isolated kidney 103–111
- Anaemia, inflammation 453–460
- Anaesthesia  
  pentobarbitone 549–551  
  renal haemodynamics 469–471
- Angiotensin II  
  antagonist 25–29, 71–81, 461–463  
  inhibition of formation 53–62  
  kidney 173–179
- Angiotensin III  
  isoprenaline 401–407
- Antidiuresis, hydrochlorothiazide 427–434
- Arterial pressure  
  indomethacin 359–365  
  renin 13–18
- Arterial pressure *see also* Hypertension
- Artery, noradrenaline concentration 545–547
- Aspartate, whole-body protein turnover 281–283
- Asthma  
  basophils, eosinophils and histamine 39–45  
  blood gases 389–396
- Asucrasia 181–185
- Baroreflex, sino-aortic 241–247
- Basophils, asthma 39–45
- Bayes' theorem 477–479
- Bence-Jones protein, isolated kidney 113–120
- Bicarbonate  
  excretion in ureterosigmoid anastomosis 305–312  
  metabolism of isolated kidney 103–111
- Bile acid clearance 499–508
- Bilirubin, metabolism 327–337
- Biochemical discrimination, Hurler and Scheie syndromes 265–272
- Blood flow, general anaesthesia 469–471

- Blood pressure  
  indomethacin 359–365  
  renin 13–18
- Blood pressure *see also* Hypertension
- Bone marrow, porphyrin biosynthesis 63–70
- Bone  
  acid–base buffering 19–23  
  femur fractures in elderly 93–101  
  osteoporosis 167–171
- Brush border, intestinal  
  disaccharidases 181–185  
   $\alpha$ -glucosidase 181–185  
  peptide hydrolysis 217–220
- Bull with congenital erythropoietic porphyria 63–70
- Calcium  
  absorption and vitamin D 121–123  
  balance studies 89–92  
  kinetics 93–101  
  parathyroid hormone 435–443  
  protein and urinary output 285–288
- Calculi, urinary  
  dietary protein 285–288
- Carbon dioxide  
  propranolol 465–468  
  pulmonary equilibration 385–388
- Cardiac muscle *see* Myocardium
- Catecholamines  
  excretion 339–344  
  metabolism 203–210  
  saralasin 71–81
- Cell-membrane permeability 289–293\*
- Cholestasis 499–508
- Cholic acid clearance 499–508
- Chromic chloride, calcium balance studies 89–92
- Chromium sesquioxide, calcium balance studies 89–92
- Clonidine  
  blood pressure 195–201  
  sympathetic activity during sleep 509–514
- Cobalamin  
  endogenous 139–144
- Colchicine  
  acid–base balance 19–23
- Colitis, mucosal enzymes 295–303
- Colon, pathogenesis of hyperchloraemic acidosis 305–312
- Congenital porphyria, enzymes 63–70
- Contraction, myocardium 415–420
- Converting enzyme  
  renal hypertension 53–62  
  sodium intake 173–179
- Covariance analysis of airway resistance 397–400
- Creatinine, premature infants 535–544
- Cysteine–homocysteine, plasma concentrations 211–215
- Cystic fibrosis with meconium ileus 445–451
- Cytosol, kidney renin 345–350
- Deoxycorticosterone, hypertension 203–210
- Dexamethasone binding in renal adenocarcinoma 421–425
- Diabetes insipidus  
  hydrochlorothiazide 427–434  
  hypertension 273–275
- Diagnosis by elimination 477–479
- Diet  
  low-sodium 225–231  
  protein and urinary calculi 285–288
- 2,4-Dinitrophenol inhibition of intestinal absorption 217–220
- Diphosphonate  
  acid–base balance 19–23  
  skeletal muscle 257–263
- Disaccharidases, jejunal 181–185
- Diuresis, urine reinfusion 187–193
- Diuretics, immunoglobulin light chain in kidney 113–120
- Electroencephalography, peripheral nerve function 31–37
- Electrolytes, anaesthesia 549–551
- Endoplasmic reticulum, hepatic 491–497
- Energy turnover 375–384
- Enterocyte, subcellular fractionation 181–185
- Eosinophils, asthma 39–45
- Erythrocyte, morphology in hyposplenism 129–137\*
- Ethanol, hepatic metabolism 481–490\*
- Exercise  
  dynamic 545–547  
  isometric 545–547
- External radioactivity counting 145–154
- Fanconi syndrome 277–279
- Femur, fractures in elderly 93–101
- Ferrokinetics 453–460
- Fracture, bone, in elderly 93–101
- Functional residual capacity 397–400
- Galactose  
  blood glucose 249–256  
  plasma insulin 249–256
- Gilbert's disease 491–497

- Gluconeogenesis, acidosis in isolated kidney 103–111  
 Glucose transport, renal 367–374  
 Glutamine, metabolism in isolated kidney 103–111  
 Glycine, whole-body protein turnover 281–283  
 Glycocholic acid clearance 499–508  
 Glycoproteins  
   meconium mucus 445–451  
   metabolism and ethanol 481–490\*  
 Glycyl-L-leucine hydrolysis and transport 521–527  
 Gunn rat, unconjugated hyperbilirubinaemia 327–337  
  
 Haemodialysis, plasma 25-hydroxy-vitamin D 473–476  
 Haemodynamics, renal 469–471  
 Heparin, plasma lipases 155–165  
 Hip replacement, intravenous galactose 249–256  
 Histamine, asthma 39–45  
 Homocystinuria and cysteine–homocysteine 211–215  
 Hormones  
   insulin 221–223  
   parathyroid hormone 167–171, 435–443  
   thyroxine 83–88  
 Hurler syndrome 265–272  
 Hydrochlorothiazide 427–434  
 18-Hydroxycorticosterone, urinary excretion 409–414  
 Hydroxyproline, Fanconi syndrome 277–279  
 25-Hydroxy-vitamin D  
   femur fractures in elderly 93–101  
   primary osteoporosis 167–171  
   seasonal variation 473–476  
 Hyperaldosteronism 409–414  
 Hyperbilirubinaemia  
   hereditary 491–497  
   unconjugated 327–337  
 Hypercapnia  
   chronic 389–396  
   propranolol 465–468  
 Hyperparathyroidism 435–443  
 Hypertension  
    $\beta$ -adrenoreceptor antagonists 241–247  
   age 273–275  
   aldosterone excretion 409–414  
   angiotensin II antagonist 461–463  
   clonidine 195–201  
   indomethacin 359–365  
   outpatients 339–344  
 Hypertension, experimental  
   aortic ligation 25–29  
   Hypertension, experimental  
     deoxycorticosterone salt 203–210  
     neurogenic activity 25–29  
     renal, Goldblatt one-kidney one-clip 53–62  
     renal, Goldblatt two-kidney one-clip 47–52, 53–62, 71–81  
   Hypertension, renovascular  
     angiotensin blockade 53–62, 71–81  
     plasma renin activity 47–52  
     potassium excretion 47–52  
     sodium excretion 47–52  
     water excretion 47–52  
   Hyperthyroidism, quadriceps function 375–384  
   Hyposplenism 129–137\*  
   Hypothyroidism  
     plasma lipoproteins 83–88  
     quadriceps function 375–384  
   Hypoxaemia 389–396  
  
 $\alpha$ -L-Iduronidase, Hurler and Scheie syndromes 265–272  
 Immune responses, spleen 129–137\*  
 Immunoglobulin light chain, isolated kidney 113–120  
 Indomethacin 359–365  
 Injury  
   intravenous galactose 249–256  
   neutrophil granulocytes 295–303  
 Insulin, skeletal muscle protein synthesis 221–223  
 Intestine  
   amino acid transport 521–527  
   dipeptide hydrolases 529–534  
   malabsorption 181–185  
   peptide absorption 217–220  
   subcellular fractionation 181–185  
   transport 1–11, 521–527  
 Intravenous infusions 225–231, 515–520  
 Isomaltase, intestinal 181–185  
 Isoprenaline, angiotensin III 401–407  
  
 Jejunum  
   aminopeptidase 1–11  
   disaccharidases 181–185  
   subcellular fractionation 181–185  
   transport 1–11  
 Juxtaglomerular apparatus 173–179  
  
 Kallikrein  
   inhibitor 351–357  
   renin activation 351–357  
  
 Kidney  
   acid–base changes after nephrectomy 19–23  
   ammonia production 103–111  
   anaesthesia and haemodynamics 469–471

**Kidney**

- angiotensin II 173–179
  - blood flow 71–81
  - cortical homogenate renin 345–350
  - failure 155–165, 435–443
  - glucose transport 367–365
  - immunoglobulin light chain 113–120
  - indomethacin 359–365
  - juxtaglomerular apparatus 173–179
  - mineralocorticoid receptors 421–425
  - phosphate absorption and lactate 125–127
  - phosphate transport 367–374
  - plasma 25-hydroxy-vitamin D 473–476
  - porphyrin biosynthesis 63–70
  - protein transport 113–120
  - proximal tubular function 427–434
  - renin secretion 233–240
  - sodium transport 367–374
  - transplantation and lipases 155–165
- Kidney disease**
- chronic renal failure 155–165, 435–443
  - immunoglobulin light chain 113–120
  - plasma 25-hydroxy-vitamin D 473–476
- Lactase, intestinal** 181–185
- Lactate, sodium, phosphate renal absorption** 125–127
- Lactoferrin turnover** 453–460
- Leucine, whole-body protein turnover** 281–283
- Leucocytes**
- asthma 39–45
  - tissue injury 295–303
- L-Leucylglycylglycylglycine, intestinal transport** 1–11
- Lipase, plasma** 155–165
- Lipid**
- hyperbilirubinaemia 327–337
  - metabolism and ethanol 481–490\*
- Lipoprotein, plasma, primary hypothyroidism** 83–88
- Liver**
- adenylate cyclase system 315–325
  - bile acid clearance 499–508
  - ethanol 481–490\*
  - foetal 313–325
  - function tests 31–37
  - hyperglycaemia 249–256
  - porphyrin biosynthesis 63–70
  - subcellular fractionation 491–497
- Liver disease**
- bile acid clearance 499–508
  - cirrhosis 31–37, 313–325, 481–490\*
  - Gilbert's syndrome 491–497
  - peripheral nerve function in 31–37

**Lung**

- carbon dioxide equilibration 385–388
  - functional residual capacity 397–400
  - volume 397–400
  - water compartments 145–154
- Lysosomes in Gilbert's syndrome** 491–497
- Macula densa** 173–179
- Magnesium, absorption and vitamin D** 121–123
- Maleic acid, Fanconi syndrome** 277–279
- Maltase, intestinal** 181–185
- Mathematical analysis of clinical diagnosis** 477–479
- Meconium mucus glycoproteins** 445–451
- Membrane, liver** 313–325
- Membrane digestion**
- intestinal 217–220
  - permeability 289–293\*
- Metabolism, calcium balance** 89–92
- 3-Methylhistidine, premature infants** 535–544
- Mineralocorticoid receptors in renal adenocarcinoma** 421–425
- Mixed disulphide, plasma** 211–215
- Mucus glycoproteins of meconium** 445–451
- Muramidase, rectal mucosa** 295–303
- Muscle-fibre types** 375–384
- Muscle, skeletal**
- energy turnover 375–384
  - fibre-type composition 375–384
  - pentobarbitone anaesthesia 549–551
  - protein degradation 535–544
  - protein synthesis 221–223
  - relaxation rate 375–384
  - thyroid disorders 375–384
  - vitamin D deficiency 257–263
- Myeloma, immunoglobulin light chain** 113–120
- Myocardium**
- ouabain 415–420
  - pentobarbitone anaesthesia 549–551
- Natriuresis, urine reinfusion** 187–193
- Natriuretic factor** 187–193
- Nephrectomy**
- acid–base changes 19–23
  - renal hypertension 25–29
- Nerve conduction velocity in liver disease** 31–37
- Neurogenic activity, renal hypertension** 25–29
- Neutrophil granulocytes**
- intravascular senescence 453–460
  - tissue injury 295–303
- Nitrogen balance, premature infants** 535–544
- Noradrenaline**
- clonidine 509–514
  - essential hypertension 339–344
  - sleep 509–514

- Oligosaccharide units from mucus glycoproteins 445-451
- Osteoporosis, primary, parathyroid function 167-171
- Ouabain on myocardium 415-420
- Oxalate, urinary 285-288
- Oxygen breathing, asthma 389-396
- Parathyroid gland, primary osteoporosis 167-171
- Parathyroid hormone  
fragments 435-443  
primary osteoporosis 167-171
- Pentobarbitone anaesthesia 549-551
- Peptide hydrolases  
amino acids 521-527  
intestinal 521-527, 529-534  
rectal mucosa 295-303
- Peptides  
initiation 221-223  
intestinal absorption 217-220  
intestinal hydrolysis 529-534  
intestinal transport 521-527
- Peptiduria  
Fanconi syndrome 277-279
- pH, intracellular 19-23
- Phlorhizin, renal transport 367-374
- Phosphate  
absorption and sodium lactate 125-127  
renal transport 367-374
- Plasma renin activity  
 $\beta$ -adrenoreceptor stimulation 13-18  
renal hypertension 25-29, 47-52
- Porphobilinogen 63-70
- Porphyrin biosynthesis 63-70
- Potassium  
anaesthesia 549-551  
excretion in renal hypertension 47-52  
intracellular 549-551  
membrane permeability 289-293\*  
myocardium exchange 415-420  
sodium pump 289-293\*
- Premature infants, muscle protein degradation 535-544
- Proline, Fanconi syndrome 277-279
- Propranolol, ventilation 465-468
- Prostaglandins, inhibition of synthesis 359-365
- Protein  
metabolism and ethanol 481-490\*  
renal transport 113-120  
skeletal muscle 221-223, 535-544  
urinary calculi formation 285-288  
whole-body turnover 281-283
- Pseudohypoparathyroidism 435-443
- Quadriceps muscle  
function in thyroid disorders 375-384
- Regional enteritis mucosal enzymes 295-303
- Regulator for infusions 515-520
- Relaxation rate, skeletal muscle 375-384
- Renal hypertension *see* Hypertension, renovascular
- Renin  
activation by kallikrein 351-357  
angiotension II antagonist 461-463  
binding substance 345-350  
dietary sodium 173-179  
higher-molecular-weight form 345-350  
plasma interaction 233-240  
saralasin 71-81
- Resistance, flow 515-520
- Respiratory failure 389-396
- Salt-free diet 225-231
- Saralasin ([Sar<sup>1</sup>, Ala<sup>8</sup>]angiotensin II)  
angiotensin receptors 71-81  
renal hypertension 25-29  
renin release 13-18
- Sarcoplasmic reticulum, vitamin D deficiency 257-263
- Scheie syndrome 265-272
- Seasonal variation in plasma vitamin D 473-476
- Sex difference, plasma amino acids 211-215
- Sino-aortic baroreflex 241-247
- Skeletal muscle *see* Muscle
- Sleep  
clonidine and sympathetic activity 509-514
- Sodium  
anaesthesia 549-551  
excretion in renal hypertension 47-52  
excretion on low-sodium diet 225-231  
intracellular 549-551  
intravenous 225-231  
pump 289-293\*  
renal angiotensin II 173-179  
renal transport 367-374  
transport disorders 289-293\*
- Spleen  
impaired function 129-137\*  
porphyrin biosynthesis 63-70
- Starvation, bilirubin 327-337
- Succinyl-CoA synthetase, bovine congenital erythropoietic porphyria 63-70
- Sucrase-isomaltase deficiency, congenital 181-185
- Sympathetic nervous activity, essential hypertension 339-344

- Tetrahydroaldosterone, urinary excretion 409–414
- Tetrapeptide, intestinal transport 1–11
- Transcobalamins, cobalamin distribution 139–144
- Transplant, renal 473–476
- Transport  
 active 289–293\*  
 amino acids 521–527  
 disorders 289–293\*  
 intestinal 1–11  
 phlorhizin 367–374  
 renal 113–120, 367–374
- Triacylglycerol  
 kidney transplantation 155–165  
 renal failure 155–165
- Troponin C, vitamin D deficiency 257–263
- Tubular absorption *see* Absorption, renal
- Uraemia, plasma lipase 155–165
- Urea  
 diuresis by urine reinfusion 187–193  
 ureterosigmoid anastomosis 305–312
- Ureterosigmoid anastomosis 305–312
- Uric acid, urinary 285–288
- Urine  
 free aldosterone 409–414  
 reinfusion diuresis and natriuresis 187–193
- Uroporphyrin, porphyrin biosynthesis 63–70
- Uroporphyrinogen synthase, bovine congenital erythropoietic porphyria 63–70
- Valine, whole-body protein turnover 281–283
- Vein  
 infusion flow 515–520  
 noradrenaline concentration 545–547
- Venous pressure 515–520
- Ventilation-perfusion ratios 389–396
- Ventilation, propranolol 465–468
- Vitamin B<sub>12</sub>  
 distribution 139–144  
 protein binding 295–303
- Vitamin D  
 calcium absorption 121–123  
 deficiency 435–443  
 magnesium absorption 121–123  
 metabolism 93–101  
 muscle function 257–263
- Vitamin D-binding protein 167–171
- Water  
 excretion in renovascular hypertension 47–52  
 lung 145–154

## SUBJECT INDEX

First and last page numbers of papers to which entries refer are given.

Page numbers marked with an asterisk refer to Editorial Reviews.

- Absorption, intestinal  
 calcium 121–123  
 magnesium 121–123  
 peptides 217–220  
 vitamin D 121–123
- Absorption, renal, phosphate and sodium  
 lactate 125–127
- Acid–base balance  
 pulmonary carbon dioxide equilibration 385–388
- Acidosis  
 hyperchloraemic 305–312  
 isolated kidney 103–111  
 nephrectomy 19–23  
 ureterosigmoid anastomosis 305–312
- Adenocarcinoma, renal  
 mineralocorticoid receptors 421–425
- Adenosine triphosphate, sodium-transport  
 disorders 289–293
- Adenylate cyclase, liver 313–325
- $\beta$ -Adrenoreceptor  
 antagonists 241–247  
 blockade 203–210  
 isoprenaline stimulation 13–18
- Age, hypertensive responses 273–275
- Airway conductance 397–400
- Airway resistance 397–400
- Albumin, serum, pulmonary water compartments 145–154
- Alcohol, hepatic metabolism 481–490\*
- Aldosterone  
 angiotensin II antagonist 461–463  
 receptors in renal adenocarcinoma 421–425  
 urinary excretion 409–414
- Aldosterone-18-glucuronide, urinary excretion 409–414
- Alkalosis, pulmonary carbon dioxide equilibration 385–388
- Alveolar–arterial difference 385–388
- Amino acids  
 intestinal transport 521–527  
 sex difference in plasma concentrations 211–215  
 skeletal muscle proteins 221–223
- $\delta$ -Aminolaevulinate dehydratase, bovine congenital erythropoietic porphyria 63–70
- $\delta$ -Aminolaevulinate synthase, bovine congenital erythropoietic porphyria 63–70
- Amino-peptidase, jejunal 1–11
- Ammonia  
 excretion in ureterosigmoid anastomosis 305–312  
 metabolism of isolated kidney 103–111
- Anaemia, inflammation 453–460
- Anaesthesia  
 pentobarbitone 549–551  
 renal haemodynamics 469–471
- Angiotensin II  
 antagonist 25–29, 71–81, 461–463  
 inhibition of formation 53–62  
 kidney 173–179
- Angiotensin III  
 isoprenaline 401–407
- Antidiuresis, hydrochlorothiazide 427–434
- Arterial pressure  
 indomethacin 359–365  
 renin 13–18
- Arterial pressure *see also* Hypertension
- Artery, noradrenaline concentration 545–547
- Aspartate, whole-body protein turnover 281–283
- Asthma  
 basophils, eosinophils and histamine 39–45  
 blood gases 389–396
- Asucrasia 181–185
- Baroreflex, sino-aortic 241–247
- Basophils, asthma 39–45
- Bayes' theorem 477–479
- Bence-Jones protein, isolated kidney 113–120
- Bicarbonate  
 excretion in ureterosigmoid anastomosis 305–312  
 metabolism of isolated kidney 103–111
- Bile acid clearance 499–508
- Bilirubin, metabolism 327–337
- Biochemical discrimination, Hurler and Scheie syndromes 265–272
- Blood flow, general anaesthesia 469–471

- Blood pressure  
  indomethacin 359–365  
  renin 13–18
- Blood pressure *see also* Hypertension
- Bone marrow, porphyrin biosynthesis 63–70
- Bone  
  acid–base buffering 19–23  
  femur fractures in elderly 93–101  
  osteoporosis 167–171
- Brush border, intestinal  
  disaccharidases 181–185  
   $\alpha$ -glucosidase 181–185  
  peptide hydrolysis 217–220
- Bull with congenital erythropoietic porphyria 63–70
- Calcium  
  absorption and vitamin D 121–123  
  balance studies 89–92  
  kinetics 93–101  
  parathyroid hormone 435–443  
  protein and urinary output 285–288
- Calculi, urinary  
  dietary protein 285–288
- Carbon dioxide  
  propranolol 465–468  
  pulmonary equilibration 385–388
- Cardiac muscle *see* Myocardium
- Catecholamines  
  excretion 339–344  
  metabolism 203–210  
  saralasin 71–81
- Cell-membrane permeability 289–293\*
- Cholestasis 499–508
- Cholic acid clearance 499–508
- Chromic chloride, calcium balance studies 89–92
- Chromium sesquioxide, calcium balance studies 89–92
- Clonidine  
  blood pressure 195–201  
  sympathetic activity during sleep 509–514
- Cobalamin  
  endogenous 139–144
- Colchicine  
  acid–base balance 19–23
- Colitis, mucosal enzymes 295–303
- Colon, pathogenesis of hyperchloraemic acidosis 305–312
- Congenital porphyria, enzymes 63–70
- Contraction, myocardium 415–420
- Converting enzyme  
  renal hypertension 53–62  
  sodium intake 173–179
- Covariance analysis of airway resistance 397–400
- Creatinine, premature infants 535–544
- Cysteine–homocysteine, plasma concentrations 211–215
- Cystic fibrosis with meconium ileus 445–451
- Cytosol, kidney renin 345–350
- Deoxycorticosterone, hypertension 203–210
- Dexamethasone binding in renal adenocarcinoma 421–425
- Diabetes insipidus  
  hydrochlorothiazide 427–434  
  hypertension 273–275
- Diagnosis by elimination 477–479
- Diet  
  low-sodium 225–231  
  protein and urinary calculi 285–288
- 2,4-Dinitrophenol inhibition of intestinal absorption 217–220
- Diphosphonate  
  acid–base balance 19–23  
  skeletal muscle 257–263
- Disaccharidases, jejunal 181–185
- Diuresis, urine reinfusion 187–193
- Diuretics, immunoglobulin light chain in kidney 113–120
- Electroencephalography, peripheral nerve function 31–37
- Electrolytes, anaesthesia 549–551
- Endoplasmic reticulum, hepatic 491–497
- Energy turnover 375–384
- Enterocyte, subcellular fractionation 181–185
- Eosinophils, asthma 39–45
- Erythrocyte, morphology in hyposplenism 129–137\*
- Ethanol, hepatic metabolism 481–490\*
- Exercise  
  dynamic 545–547  
  isometric 545–547
- External radioactivity counting 145–154
- Fanconi syndrome 277–279
- Femur, fractures in elderly 93–101
- Ferrokinetics 453–460
- Fracture, bone, in elderly 93–101
- Functional residual capacity 397–400
- Galactose  
  blood glucose 249–256  
  plasma insulin 249–256
- Gilbert's disease 491–497

- Gluconeogenesis, acidosis in isolated kidney 103–111  
 Glucose transport, renal 367–374  
 Glutamine, metabolism in isolated kidney 103–111  
 Glycine, whole-body protein turnover 281–283  
 Glycocholic acid clearance 499–508  
 Glycoproteins  
   meconium mucus 445–451  
   metabolism and ethanol 481–490\*  
 Glycyl-L-leucine hydrolysis and transport 521–527  
 Gunn rat, unconjugated hyperbilirubinaemia 327–337  
  
 Haemodialysis, plasma 25-hydroxy-vitamin D 473–476  
 Haemodynamics, renal 469–471  
 Heparin, plasma lipases 155–165  
 Hip replacement, intravenous galactose 249–256  
 Histamine, asthma 39–45  
 Homocystinuria and cysteine–homocysteine 211–215  
 Hormones  
   insulin 221–223  
   parathyroid hormone 167–171, 435–443  
   thyroxine 83–88  
 Hurler syndrome 265–272  
 Hydrochlorothiazide 427–434  
 18-Hydroxycorticosterone, urinary excretion 409–414  
 Hydroxyproline, Fanconi syndrome 277–279  
 25-Hydroxy-vitamin D  
   femur fractures in elderly 93–101  
   primary osteoporosis 167–171  
   seasonal variation 473–476  
 Hyperaldosteronism 409–414  
 Hyperbilirubinaemia  
   hereditary 491–497  
   unconjugated 327–337  
 Hypercapnia  
   chronic 389–396  
   propranolol 465–468  
 Hyperparathyroidism 435–443  
 Hypertension  
    $\beta$ -adrenoreceptor antagonists 241–247  
   age 273–275  
   aldosterone excretion 409–414  
   angiotensin II antagonist 461–463  
   clonidine 195–201  
   indomethacin 359–365  
   outpatients 339–344  
 Hypertension, experimental  
   aortic ligation 25–29  
   Hypertension, experimental  
     deoxycorticosterone salt 203–210  
     neurogenic activity 25–29  
     renal, Goldblatt one-kidney one-clip 53–62  
     renal, Goldblatt two-kidney one-clip 47–52, 53–62, 71–81  
   Hypertension, renovascular  
     angiotensin blockade 53–62, 71–81  
     plasma renin activity 47–52  
     potassium excretion 47–52  
     sodium excretion 47–52  
     water excretion 47–52  
   Hyperthyroidism, quadriceps function 375–384  
   Hyposplenism 129–137\*  
   Hypothyroidism  
     plasma lipoproteins 83–88  
     quadriceps function 375–384  
   Hypoxaemia 389–396  
  
 $\alpha$ -L-Iduronidase, Hurler and Scheie syndromes 265–272  
 Immune responses, spleen 129–137\*  
 Immunoglobulin light chain, isolated kidney 113–120  
 Indomethacin 359–365  
 Injury  
   intravenous galactose 249–256  
   neutrophil granulocytes 295–303  
 Insulin, skeletal muscle protein synthesis 221–223  
 Intestine  
   amino acid transport 521–527  
   dipeptide hydrolases 529–534  
   malabsorption 181–185  
   peptide absorption 217–220  
   subcellular fractionation 181–185  
   transport 1–11, 521–527  
 Intravenous infusions 225–231, 515–520  
 Isomaltase, intestinal 181–185  
 Isoprenaline, angiotensin III 401–407  
  
 Jejunum  
   aminopeptidase 1–11  
   disaccharidases 181–185  
   subcellular fractionation 181–185  
   transport 1–11  
 Juxtaglomerular apparatus 173–179  
  
 Kallikrein  
   inhibitor 351–357  
   renin activation 351–357  
  
 Kidney  
   acid–base changes after nephrectomy 19–23  
   ammonia production 103–111  
   anaesthesia and haemodynamics 469–471

**Kidney**

- angiotensin II 173–179
  - blood flow 71–81
  - cortical homogenate renin 345–350
  - failure 155–165, 435–443
  - glucose transport 367–365
  - immunoglobulin light chain 113–120
  - indomethacin 359–365
  - juxtaglomerular apparatus 173–179
  - mineralocorticoid receptors 421–425
  - phosphate absorption and lactate 125–127
  - phosphate transport 367–374
  - plasma 25-hydroxy-vitamin D 473–476
  - porphyrin biosynthesis 63–70
  - protein transport 113–120
  - proximal tubular function 427–434
  - renin secretion 233–240
  - sodium transport 367–374
  - transplantation and lipases 155–165
- Kidney disease**
- chronic renal failure 155–165, 435–443
  - immunoglobulin light chain 113–120
  - plasma 25-hydroxy-vitamin D 473–476
- Lactase, intestinal** 181–185
- Lactate, sodium, phosphate renal absorption** 125–127
- Lactoferrin turnover** 453–460
- Leucine, whole-body protein turnover** 281–283
- Leucocytes**
- asthma 39–45
  - tissue injury 295–303
- L-Leucylglycylglycylglycine, intestinal transport** 1–11
- Lipase, plasma** 155–165
- Lipid**
- hyperbilirubinaemia 327–337
  - metabolism and ethanol 481–490\*
- Lipoprotein, plasma, primary hypothyroidism** 83–88
- Liver**
- adenylate cyclase system 315–325
  - bile acid clearance 499–508
  - ethanol 481–490\*
  - foetal 313–325
  - function tests 31–37
  - hyperglycaemia 249–256
  - porphyrin biosynthesis 63–70
  - subcellular fractionation 491–497
- Liver disease**
- bile acid clearance 499–508
  - cirrhosis 31–37, 313–325, 481–490\*
  - Gilbert's syndrome 491–497
  - peripheral nerve function in 31–37

**Lung**

- carbon dioxide equilibration 385–388
  - functional residual capacity 397–400
  - volume 397–400
  - water compartments 145–154
- Lysosomes in Gilbert's syndrome** 491–497
- Macula densa** 173–179
- Magnesium, absorption and vitamin D** 121–123
- Maleic acid, Fanconi syndrome** 277–279
- Maltase, intestinal** 181–185
- Mathematical analysis of clinical diagnosis** 477–479
- Meconium mucus glycoproteins** 445–451
- Membrane, liver** 313–325
- Membrane digestion**
- intestinal 217–220
  - permeability 289–293\*
- Metabolism, calcium balance** 89–92
- 3-Methylhistidine, premature infants** 535–544
- Mineralocorticoid receptors in renal adenocarcinoma** 421–425
- Mixed disulphide, plasma** 211–215
- Mucus glycoproteins of meconium** 445–451
- Muramidase, rectal mucosa** 295–303
- Muscle-fibre types** 375–384
- Muscle, skeletal**
- energy turnover 375–384
  - fibre-type composition 375–384
  - pentobarbitone anaesthesia 549–551
  - protein degradation 535–544
  - protein synthesis 221–223
  - relaxation rate 375–384
  - thyroid disorders 375–384
  - vitamin D deficiency 257–263
- Myeloma, immunoglobulin light chain** 113–120
- Myocardium**
- ouabain 415–420
  - pentobarbitone anaesthesia 549–551
- Natriuresis, urine reinfusion** 187–193
- Natriuretic factor** 187–193
- Nephrectomy**
- acid–base changes 19–23
  - renal hypertension 25–29
- Nerve conduction velocity in liver disease** 31–37
- Neurogenic activity, renal hypertension** 25–29
- Neutrophil granulocytes**
- intravascular senescence 453–460
  - tissue injury 295–303
- Nitrogen balance, premature infants** 535–544
- Noradrenaline**
- clonidine 509–514
  - essential hypertension 339–344
  - sleep 509–514

- Oligosaccharide units from mucus glycoproteins 445-451
- Osteoporosis, primary, parathyroid function 167-171
- Ouabain on myocardium 415-420
- Oxalate, urinary 285-288
- Oxygen breathing, asthma 389-396
- Parathyroid gland, primary osteoporosis 167-171
- Parathyroid hormone  
fragments 435-443  
primary osteoporosis 167-171
- Pentobarbitone anaesthesia 549-551
- Peptide hydrolases  
amino acids 521-527  
intestinal 521-527, 529-534  
rectal mucosa 295-303
- Peptides  
initiation 221-223  
intestinal absorption 217-220  
intestinal hydrolysis 529-534  
intestinal transport 521-527
- Peptiduria  
Fanconi syndrome 277-279
- pH, intracellular 19-23
- Phlorhizin, renal transport 367-374
- Phosphate  
absorption and sodium lactate 125-127  
renal transport 367-374
- Plasma renin activity  
 $\beta$ -adrenoreceptor stimulation 13-18  
renal hypertension 25-29, 47-52
- Porphobilinogen 63-70
- Porphyrin biosynthesis 63-70
- Potassium  
anaesthesia 549-551  
excretion in renal hypertension 47-52  
intracellular 549-551  
membrane permeability 289-293\*  
myocardium exchange 415-420  
sodium pump 289-293\*
- Premature infants, muscle protein degradation 535-544
- Proline, Fanconi syndrome 277-279
- Propranolol, ventilation 465-468
- Prostaglandins, inhibition of synthesis 359-365
- Protein  
metabolism and ethanol 481-490\*  
renal transport 113-120  
skeletal muscle 221-223, 535-544  
urinary calculi formation 285-288  
whole-body turnover 281-283
- Pseudohypoparathyroidism 435-443
- Quadriceps muscle  
function in thyroid disorders 375-384
- Regional enteritis mucosal enzymes 295-303
- Regulator for infusions 515-520
- Relaxation rate, skeletal muscle 375-384
- Renal hypertension *see* Hypertension, renovascular
- Renin  
activation by kallikrein 351-357  
angiotension II antagonist 461-463  
binding substance 345-350  
dietary sodium 173-179  
higher-molecular-weight form 345-350  
plasma interaction 233-240  
saralasin 71-81
- Resistance, flow 515-520
- Respiratory failure 389-396
- Salt-free diet 225-231
- Saralasin ([Sar<sup>1</sup>, Ala<sup>8</sup>]angiotensin II)  
angiotensin receptors 71-81  
renal hypertension 25-29  
renin release 13-18
- Sarcoplasmic reticulum, vitamin D deficiency 257-263
- Scheie syndrome 265-272
- Seasonal variation in plasma vitamin D 473-476
- Sex difference, plasma amino acids 211-215
- Sino-aortic baroreflex 241-247
- Skeletal muscle *see* Muscle
- Sleep  
clonidine and sympathetic activity 509-514
- Sodium  
anaesthesia 549-551  
excretion in renal hypertension 47-52  
excretion on low-sodium diet 225-231  
intracellular 549-551  
intravenous 225-231  
pump 289-293\*  
renal angiotensin II 173-179  
renal transport 367-374  
transport disorders 289-293\*
- Spleen  
impaired function 129-137\*  
porphyrin biosynthesis 63-70
- Starvation, bilirubin 327-337
- Succinyl-CoA synthetase, bovine congenital erythropoietic porphyria 63-70
- Sucrase-isomaltase deficiency, congenital 181-185
- Sympathetic nervous activity, essential hypertension 339-344

- Tetrahydroaldosterone, urinary excretion 409–414
- Tetrapeptide, intestinal transport 1–11
- Transcobalamins, cobalamin distribution 139–144
- Transplant, renal 473–476
- Transport  
 active 289–293\*  
 amino acids 521–527  
 disorders 289–293\*  
 intestinal 1–11  
 phlorhizin 367–374  
 renal 113–120, 367–374
- Triacylglycerol  
 kidney transplantation 155–165  
 renal failure 155–165
- Troponin C, vitamin D deficiency 257–263
- Tubular absorption *see* Absorption, renal
- Uraemia, plasma lipase 155–165
- Urea  
 diuresis by urine reinfusion 187–193  
 ureterosigmoid anastomosis 305–312
- Ureterosigmoid anastomosis 305–312
- Uric acid, urinary 285–288
- Urine  
 free aldosterone 409–414  
 reinfusion diuresis and natriuresis 187–193
- Uroporphyrin, porphyrin biosynthesis 63–70
- Uroporphyrinogen synthase, bovine congenital erythropoietic porphyria 63–70
- Valine, whole-body protein turnover 281–283
- Vein  
 infusion flow 515–520  
 noradrenaline concentration 545–547
- Venous pressure 515–520
- Ventilation-perfusion ratios 389–396
- Ventilation, propranolol 465–468
- Vitamin B<sub>12</sub>  
 distribution 139–144  
 protein binding 295–303
- Vitamin D  
 calcium absorption 121–123  
 deficiency 435–443  
 magnesium absorption 121–123  
 metabolism 93–101  
 muscle function 257–263
- Vitamin D-binding protein 167–171
- Water  
 excretion in renovascular hypertension 47–52  
 lung 145–154